Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BMXWC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-FGFR2/4 mAb-20811 CX1-1-DM1
|
|||||
| Synonyms |
Anti-FGFR2/4-mAb-20811-CX1-1-DM1
Click to Show/Hide
|
|||||
| Organization |
Novartis AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Colorectal cancer [ICD11:2B91]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3-4
|
|||||
| Antibody Name |
Anti-FGFR2/4 mAb 20811
|
Antibody Info | ||||
| Antigen Name |
Fibroblast growth factor receptor 2 (FGFR2); Fibroblast growth factor receptor 4 (FGFR4)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.